Method for treating neoplasms using hollow silica spheres

Patent metadata

Field	Value
Publication number	US-11491110-B2
Application number	US-201916403049-A
Country	US
Kind code	B2
Filing date	May 3, 2019
Priority date	May 3, 2019
Publication date	Nov 8, 2022
Grant date	Nov 8, 2022

Abstract

The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe3O4, as well as compositions containing HSS.

First claim

The invention claimed is:

1. A method for treating a subject having a cancer selected from the group consisting of a colon cancer and a colorectal cancer, comprising:
administering to the subject an aqueous composition comprising Fe 3 O 4 -hollow silica spheres (“Fe-HSS”),
wherein the aqueous composition is administered in an amount sufficient to induce nuclear condensation, augmentation, and disintegration of cells of the cancer,
wherein the Fe-HSS are calcined,
wherein the surfaces of the Fe-HSS comprise no more than 0.1 mol. % phenyl or aryl groups, relative to an average uncalcined Fe-HSS,
wherein the Fe-HSS have a hollow core space containing plural individual particles of Fe 3 O 4 having an average diameter in a range of from 9.5 nm to 21.3 nm and the Fe 3 O 4 has a spinel structure,
wherein the hollow silica spheres of the Fe 3 O 4 -hollow silica spheres have a core-shell structure with shells larger in thickness than cores, and the hollow silica spheres have an average diameter in a range of from 415 to 615 nm, and
wherein the particles of Fe 3 O 4 are present in a range of from 0.1 to 10 wt. % of a combined weight of the HSS and Fe 3 O 4 in the Fe-HSS.

2. The method of claim 1 , wherein the hollow silica spheres are prepared by a process comprising hydrolysis of a mixture comprising Fe 3 O 4 and phenyl-tri-methoxysilane or another hydrolyzable aryl silane followed by condensation with a hydroxide base.

3. The method of claim 1 , wherein the surfaces of the Fe-HSS are free of phenyl or aryl groups.

4. The method of claim 1 , wherein the Fe-HSS further comprise at least one anticancer drug or agent.

5. The method of claim 1 , wherein the aqueous composition comprising the HSS is administered in situ to the site of a tumor or a tissue or organ containing cancer cells.

6. The method of claim 1 , wherein the composition comprising the HSS is administered intravenously, intramuscularly, subcutaneously, or otherwise parenterally.

7. The method of claim 1 , wherein the Fe-HSS has a BET surface area in a range of from 350 to 450 m 2 /g.

8. The method of claim 1 , wherein the Fe-HSS has an average shell thickness in a range of from 150 to 210 nm.

9. The method of claim 1 , wherein the Fe-HSS alone is sufficient to cause nucleus condensation and nuclear augmentation in the aqueous solution in a range of from 1 to 3 mg/mL.

10. The method of claim 1 , wherein the surfaces of the Fe-HSS comprise no more than 0.05 mol. % phenyl or aryl groups, relative to an average uncalcined Fe-HSS.

11. The method of claim 1 , wherein the surfaces of the Fe-HSS comprise no more than 0.02 mol. % phenyl or aryl groups, relative to an average uncalcined Fe-HSS.

12. The method of claim 1 , wherein the surfaces of the Fe-HSS comprise no more than 0.01 mol. % phenyl or aryl groups, relative to an average uncalcined Fe-HSS.

Assignees

• Univ Imam Abdulrahman Bin Faisal

Inventors

• Bozkurt Ayhan
• Anil Seyda Tugba Gunday
• Khan Firdos Alam
• Akhtar Sultan

Classifications

• A61K9/0043

  Nose · CPC title

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• A61K33/26

  Iron; Compounds thereof · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K9/1611

  Inorganic compounds · CPC title